Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma Journal Article


Authors: Wudhikarn, K.; Palomba, M. L.; Pennisi, M.; Garcia-Recio, M.; Flynn, J. R.; Devlin, S. M.; Afuye, A.; Silverberg, M. L.; Maloy, M. A.; Shah, G. L.; Scordo, M.; Dahi, P. B.; Sauter, C. S.; Batlevi, C. L.; Santomasso, B. D.; Mead, E.; Seo, S. K.; Perales, M. A.
Article Title: Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma
Abstract: CD19-targeted chimeric antigen receptor (CAR) T cell therapy is an effective treatment for diffuse large B cell lymphoma (DLBCL). In addition to cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity (ICANS), B cell aplasia and hypogammaglobulinemia are common toxicities predisposing these patients to infections. We analyzed 60 patients with DLBCL treated with FDA-approved CD19 CAR T cells and report the incidence, risk factors, and management of infections during the first year after treatment. A total of 101 infectious events were observed, including 25 mild, 51 moderate, 23 severe, 1 life-threatening, and 1 fatal infection. Bacteria were the most common causative pathogens. The cumulative incidence of overall, bacterial, severe bacterial, viral, and fungal infection at 1 year were 63.3%, 57.2%, 29.6%, 44.7%, and 4%, respectively. In multivariate analyses, the use of systemic corticosteroids for the management of CRS or ICANS was associated with an increased risk of infections and prolonged admission. Impaired performance status and history of infections within 30 days before CAR T cell therapy was a risk factor for severe bacterial infection. In conclusion, infections were common within the first 60 days after CAR T cell therapy, however, they were not associated with an increased risk of death. © 2020, The Author(s).
Keywords: adult; aged; major clinical study; fludarabine; neutropenia; gemcitabine; rituximab; neurotoxicity; cohort analysis; aciclovir; bendamustine; cyclophosphamide; risk factor; lymphocytopenia; multivariate analysis; virus infection; corticosteroid; disease predisposition; cotrimoxazole; bacterial infection; immunoglobulin deficiency; antibiotic prophylaxis; fluconazole; pentamidine; mycosis; voriconazole; infection risk; cd19 antigen; cytokine release syndrome; diffuse large b cell lymphoma; human; male; female; article; tisagenlecleucel t; chimeric antigen receptor t-cell immunotherapy; axicabtagene ciloleucel
Journal Title: Blood Cancer Journal
Volume: 10
ISSN: 2044-5385
Publisher: Nature Publishing Group  
Date Published: 2020-08-05
Start Page: 79
Language: English
DOI: 10.1038/s41408-020-00346-7
PUBMED: 32759935
PROVIDER: scopus
PMCID: PMC7405315
DOI/URL:
Notes: Article -- Export Date: 1 September 2020 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Susan Seo
    122 Seo
  2. Maria Lia Palomba
    441 Palomba
  3. Craig Steven Sauter
    335 Sauter
  4. Miguel-Angel Perales
    938 Perales
  5. Molly Anna Maloy
    269 Maloy
  6. Sean McCarthy Devlin
    613 Devlin
  7. Parastoo Bahrami Dahi
    304 Dahi
  8. Michael Scordo
    382 Scordo
  9. Connie Wing-Ching Lee Batlevi
    177 Batlevi
  10. Gunjan Lalitchandra Shah
    440 Shah
  11. Elena   Mead
    53 Mead
  12. Aishat Olaide Afuye
    16 Afuye
  13. Jessica Flynn
    182 Flynn
  14. Martina Pennisi
    25 Pennisi